These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38158474)

  • 21. Structured edible lipid-based particle systems for oral drug-delivery.
    Ashkar A; Sosnik A; Davidovich-Pinhas M
    Biotechnol Adv; 2022; 54():107789. PubMed ID: 34186162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Curcumin-loaded solid lipid nanoparticles with Brij78 and TPGS improved in vivo oral bioavailability and in situ intestinal absorption of curcumin.
    Ji H; Tang J; Li M; Ren J; Zheng N; Wu L
    Drug Deliv; 2016; 23(2):459-70. PubMed ID: 24892628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nanostructured Lipid Carriers for Oral Bioavailability Enhancement of Exemestane: Formulation Design, In Vitro, Ex Vivo, and In Vivo Studies.
    Singh A; Neupane YR; Mangla B; Kohli K
    J Pharm Sci; 2019 Oct; 108(10):3382-3395. PubMed ID: 31201904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs?
    Das S; Ng WK; Tan RB
    Eur J Pharm Sci; 2012 Aug; 47(1):139-51. PubMed ID: 22664358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of Domperidone Solid Lipid Nanoparticles: In Vitro and In Vivo Characterization.
    Shazly GA; Alshehri S; Ibrahim MA; Tawfeek HM; Razik JA; Hassan YA; Shakeel F
    AAPS PharmSciTech; 2018 May; 19(4):1712-1719. PubMed ID: 29532427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative study of oral lipid nanoparticle formulations (LNFs) for chemical stabilization of antitubercular drugs: physicochemical and cellular evaluation.
    Banerjee S; Roy S; Nath Bhaumik K; Kshetrapal P; Pillai J
    Artif Cells Nanomed Biotechnol; 2018; 46(sup1):540-558. PubMed ID: 29373927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Streptomycin sulphate loaded solid lipid nanoparticles show enhanced uptake in macrophage, lower MIC in Mycobacterium and improved oral bioavailability.
    Singh M; Schiavone N; Papucci L; Maan P; Kaur J; Singh G; Nandi U; Nosi D; Tani A; Khuller GK; Priya M; Singh R; Kaur IP
    Eur J Pharm Biopharm; 2021 Mar; 160():100-124. PubMed ID: 33497794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nanostructured lipid (NLCs) carriers as a bioavailability enhancement tool for oral administration.
    Gaba B; Fazil M; Ali A; Baboota S; Sahni JK; Ali J
    Drug Deliv; 2015; 22(6):691-700. PubMed ID: 24670099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Challenges in Oral Drug Delivery and Applications of Lipid Nanoparticles as Potent Oral Drug Carriers for Managing Cardiovascular Risk Factors.
    Okur NÜ; Siafaka PI; Gökçe EH
    Curr Pharm Biotechnol; 2021; 22(7):892-905. PubMed ID: 32753006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulating Drug Release and Enhancing the Oral Bioavailability of Torcetrapib with Solid Lipid Dispersion Formulations.
    Liu Y; Salituro GM; Lee KJ; Bak A; Leung DH
    AAPS PharmSciTech; 2015 Oct; 16(5):1091-100. PubMed ID: 25690735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy?
    Qu J; Zhang L; Chen Z; Mao G; Gao Z; Lai X; Zhu X; Zhu J
    Drug Deliv; 2016 Nov; 23(9):3408-3416. PubMed ID: 27181462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Solid lipid nanoparticles and nanostructured lipid carriers: a review of the methods of manufacture and routes of administration.
    Akbari J; Saeedi M; Ahmadi F; Hashemi SMH; Babaei A; Yaddollahi S; Rostamkalaei SS; Asare-Addo K; Nokhodchi A
    Pharm Dev Technol; 2022 Jun; 27(5):525-544. PubMed ID: 35635506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and pharmacokinetic evaluation of a self-nanoemulsifying drug delivery system for the oral delivery of cannabidiol.
    Kok LY; Bannigan P; Sanaee F; Evans JC; Dunne M; Regenold M; Ahmed L; Dubins D; Allen C
    Eur J Pharm Sci; 2022 Jan; 168():106058. PubMed ID: 34763088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel.
    Pandita D; Ahuja A; Lather V; Benjamin B; Dutta T; Velpandian T; Khar RK
    AAPS PharmSciTech; 2011 Jun; 12(2):712-22. PubMed ID: 21637945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir.
    Seyfoddin A; Al-Kassas R
    Drug Dev Ind Pharm; 2013 Apr; 39(4):508-19. PubMed ID: 22424312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
    Dudhipala N; Veerabrahma K
    Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The influence on the oral bioavailability of solubilized and suspended drug in a lipid nanoparticle formulation: In vitro and in vivo evaluation.
    Elbrink K; Van Hees S; Roelant D; Loomans T; Holm R; Kiekens F
    Eur J Pharm Biopharm; 2022 Oct; 179():1-10. PubMed ID: 36031014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancing the Oral Absorption of Kinase Inhibitors Using Lipophilic Salts and Lipid-Based Formulations.
    Williams HD; Ford L; Han S; Tangso KJ; Lim S; Shackleford DM; Vodak DT; Benameur H; Pouton CW; Scammells PJ; Porter CJH
    Mol Pharm; 2018 Dec; 15(12):5678-5696. PubMed ID: 30376336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Infant formula as a solid lipid dose form for enhancement of the oral bioavailability of cannabidiol for paediatric patients.
    Huang S; Pham AC; Salim M; Eason T; Ramirez G; Boyd BJ
    Int J Pharm; 2024 Jul; 660():124257. PubMed ID: 38782154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of a Solid Lipid Nanoparticle Formulation on the Bioavailability of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine After Oral Administration.
    Valdes SA; Alzhrani RF; Lansakara-P DSP; Cui Z
    AAPS PharmSciTech; 2020 Jan; 21(3):77. PubMed ID: 31970527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.